Recommendation: We recommend that non-HDL-C and apo B should continue to be considered alternate targets to LDL-C to evaluate risk in adults (Strong Recommendation, High Quality Evidence).

Values and preferences: As clinicians are most familiar with LDL-C we continue to recommend its use as the primary target, but anticipate a shift to preferential use of non HDL-C or apo B in the future.